Keeping Track: Two Melanoma Approvals; Pfizer Discloses Retacrit Complete Response
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Bristol Offers Yervoy For Free In New Early Melanoma Indication
New program gives free treatment with the checkpoint inhibitor for up to three years to patients taking 10 mg/kg dose as adjuvant therapy after surgery.
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.